Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate and Corticosteroid for Acute Graft vs. Host Disease
NCT04960644Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Overall Response Rate at 10 days. Started Jun 2021; status: completed.
02
Drugs
methotrexate
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04960644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04960644.